Methods for the Construction of Recombinant Oncolytic Myxoma Viruses.
Animals
Chlorocebus aethiops
Cloning, Molecular
/ methods
Genes, Reporter
Genetic Engineering
/ methods
Genome, Viral
Green Fluorescent Proteins
/ genetics
HeLa Cells
Humans
Luminescent Proteins
/ genetics
Myxoma virus
/ genetics
Oncolytic Virotherapy
/ methods
Oncolytic Viruses
/ genetics
Plasmids
/ chemistry
Rabbits
Recombinant Proteins
/ biosynthesis
Transgenes
Vero Cells
Armed oncolytic virus
Engineered virus
Myxoma virus
Oncolytic virotherapy
Oncolytic virus
Poxvirus
Recombinant virus
Viral vector
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
27
10
2020
pubmed:
28
10
2020
medline:
27
3
2021
Statut:
ppublish
Résumé
Myxoma virus (MYXV) has proven to be an effective candidate for oncolytic virotherapy in many preclinical cancer models. As a nonhuman pathogen, MYXV does not need to overcome any preexisting antiviral immunity, and its DNA cannot integrate into the host genome, making it an extremely safe vector. Moreover, the large dsDNA genome of MYXV allows the insertion of multiple transgenes and the design of engineered recombinant oncolytic viruses (OVs) with enhanced immunostimulatory or other desired properties. In this chapter, we describe detailed protocols for the generation and characterization of transgene-armed recombinant MYXV vectors.
Identifiants
pubmed: 33108657
doi: 10.1007/978-1-0716-1012-1_4
pmc: PMC8082691
mid: NIHMS1691314
doi:
Substances chimiques
Luminescent Proteins
0
Recombinant Proteins
0
enhanced green fluorescent protein
0
fluorescent protein 583
0
Green Fluorescent Proteins
147336-22-9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
63-75Subventions
Organisme : NIAID NIH HHS
ID : R01 AI080607
Pays : United States
Références
Vaccine. 2013 Sep 6;31(39):4252-8
pubmed: 23726825
Curr Protoc Microbiol. 2010 May;Chapter 14:Unit 14A.1
pubmed: 20440681
Methods Mol Biol. 2018;1826:73-86
pubmed: 30194594
Cancer Res. 2017 Jun 1;77(11):2952-2963
pubmed: 28314785
PLoS One. 2014 Oct 16;9(10):e109801
pubmed: 25329832
Annu Rev Virol. 2014 Sep 1;1(1):119-141
pubmed: 25839047
Methods Mol Biol. 2012;890:59-92
pubmed: 22688761
Expert Opin Biol Ther. 2019 Jun;19(6):561-573
pubmed: 30919708
Nat Rev Microbiol. 2005 Mar;3(3):201-13
pubmed: 15738948
Front Oncol. 2014 Jun 17;4:155
pubmed: 24987615
Front Oncol. 2017 May 23;7:96
pubmed: 28589082
Methods Mol Biol. 2015;1312:77-86
pubmed: 26043992
Drugs Today (Barc). 2015 Sep;51(9):549-58
pubmed: 26488034